Sulfasalazine

Sulfasalazine is used in inflammatory bowel disease, rheumatoid arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a prodrug, split by colonic bacteria into 5-aminosalicylic acid (the anti-inflammatory in IBD) and sulfapyridine. Sulfapyridine carries the antibiotic-type arylamine — so people with sulfa antibiotic allergy may react.

What it does

Sulfasalazine is, structurally, a molecule of sulfapyridine linked by an azo bond to 5-aminosalicylic acid (5-ASA, also known as mesalamine or mesalazine). When taken orally, it passes through the small intestine largely intact and reaches the colon. Colonic bacteria cleave the azo bond, releasing the two components.

The 5-ASA acts locally on the colonic mucosa as an anti-inflammatory in inflammatory bowel disease. The sulfapyridine is absorbed systemically and is responsible for most of the drug's systemic side effects — and for the cross-reactivity question with sulfa antibiotic allergy.

The systemic mechanism behind sulfasalazine's effect in rheumatoid arthritis and other inflammatory joint conditions is less clearly defined; immune-modulating effects of both components have been proposed.

What it is used for

Ulcerative colitis. Long-standing use for mild to moderate disease and for maintenance of remission. Modern alternatives — mesalamine, balsalazide, olsalazine — deliver 5-ASA without the sulfa moiety and are widely used, particularly in patients with sulfa antibiotic allergy.

Rheumatoid arthritis. A traditional disease-modifying antirheumatic drug (DMARD), sometimes used alone in milder disease and as part of combination DMARD regimens. Methotrexate is generally first-line; sulfasalazine remains an option.

Juvenile idiopathic arthritis and ankylosing spondylitis — established uses, particularly for peripheral joint involvement in spondyloarthritis.

Common adverse effects

Adverse effects are largely from the sulfapyridine component:

Gastrointestinal — nausea, anorexia, abdominal discomfort, vomiting. Common at initiation and often dose-related.

Headache, dizziness, fatigue.

Rash, photosensitivity.

Hematologic effects — leukopenia (the most clinically important and the basis of routine blood monitoring), thrombocytopenia, megaloblastic anemia (folate-related — folate supplementation is sometimes added), rare agranulocytosis.

Hepatic injury — transaminase elevations, rare severe drug-induced liver injury.

Hemolysis — particularly in G6PD deficiency; testing may be considered before starting in patients from higher-prevalence populations.

Reversible male infertility — sulfasalazine reduces sperm count and motility. The effect reverses on stopping the drug. Patients planning conception may switch to a different DMARD.

Less common but important: severe cutaneous adverse reactions including SJS/TEN, DRESS, hypersensitivity pneumonitis, pancreatitis. Yellow-orange discolouration of urine, skin, and tears is a recognised harmless effect.

The sulfa allergy question

Sulfasalazine is the major exception in the cross-reactivity story. Where most non-antibiotic sulfonamides — furosemide, HCTZ, celecoxib, sulfonylureas, acetazolamide — lack the N4 arylamine and show low cross-reactivity with sulfa antibiotics, sulfasalazine generates sulfapyridine on metabolism, and sulfapyridine has the arylamine.

The practical implication: patients with a documented sulfa antibiotic allergy may react to sulfasalazine. Many clinicians choose alternative drugs in this group when alternatives exist (mesalamine for IBD, methotrexate or other DMARDs for RA). Patients with mild past reactions are sometimes started on sulfasalazine cautiously, with close follow-up, when a specific advantage is sought.

Treat sulfasalazine like a sulfa antibiotic for allergy purposes. Patients with a documented sulfa antibiotic allergy should not start sulfasalazine without explicit prescriber awareness of that label. Severe past reactions (SJS, TEN, anaphylaxis) are generally a contraindication.

Monitoring

Patients on long-term sulfasalazine typically have periodic blood tests — full blood count, liver function tests, renal function — at intervals defined by the prescriber. Closer monitoring is usual in the first months. Patients should be told about the symptoms of the more important reactions (rash, mouth sores, sore throat with fever, jaundice, unusual bruising, breathing difficulty) so they can seek assessment promptly.

Pregnancy

Sulfasalazine has been used in pregnancy in selected patients with active inflammatory disease. Folate supplementation is typically given because of the folate-antagonist effect. Decisions are made with obstetric and rheumatology/gastroenterology input. More on pregnancy.